Capital Fund Management (CFM)
ALLO icon

Capital Fund Management (CFM)’s Allogene Therapeutics ALLO Stock Holding History

Capital Fund Management (CFM)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-198,855
Closed -$982K – 1655
2023
Q1 		$982K Sell
198,855
-96,926
-33% -$622K ﹤0.01% 1275
2022
Q4 		$1.86M Buy
295,781
+230,979
+356% +$2.14M 0.01% 964
2022
Q3 		$700K Sell
64,802
-44,239
-41% -$601K 0.01% 1185
2022
Q2 		$1.24M Buy
109,041
+4,688
+4% +$41.6K 0.01% 995
2022
Q1 		$951K Buy
+104,353
New +$1.09M 0.01% 1164
2020
Q2 		– Sell
-10,342
Closed -$201K – 1000
2020
Q1 		$201K Buy
+10,342
New +$246K ﹤0.01% 1414

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Fund Management (CFM)'s ALLO Position: Q2 2023 in Review

Capital Fund Management (CFM) sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 198,855 shares — an estimated $982K sold.

Capital Fund Management (CFM) first reported a position in ALLO in Q1 2020 and held it in 6 quarters. The position peaked at $1.86M in Q4 2022. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

  • Capital Fund Management (CFM) reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 198,855 Allogene Therapeutics shares in Q2 2023, an estimated $982K.
  • Capital Fund Management (CFM) first reported a position in Allogene Therapeutics in Q1 2020 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Allogene Therapeutics position peaked at $1.86M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2023, filed 14 Aug 2023.